These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 16336087)

  • 21. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
    Sarcev T; Secen N; Zaric B; Milovancev A
    J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.
    Smith AR; Repka TL; Weigel BJ
    Pediatr Blood Cancer; 2005 Nov; 45(6):857-60. PubMed ID: 15849684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New antiemetic drugs.
    Roila F; Fatigoni S
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
    Aapro M; Johnson J
    Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
    Oo TH; Hesketh PJ
    Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced nausea and vomiting: state of the art in 2006.
    Schwartzberg L
    J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP; Madelaine I; Scotté F
    Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.
    Wickham R
    J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.
    Aapro MS; Schmoll HJ; Jahn F; Carides AD; Webb RT
    Cancer Treat Rev; 2013 Feb; 39(1):113-7. PubMed ID: 23062719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
    Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.